
-
- The Future of AI-Powered Pharmacovigilance: What’s Coming NextAfter three days at the World Drug Safety Congress 2025, I left with many thoughts about where AI is heading in pharmacovigilance (PV). Here are some of my key takeaways and beliefs about what’s next: 1. Broader adoption of AI: More companies are now applying AI to streamline operations, automate workflows, and generate reports efficiently.… Read more: The Future of AI-Powered Pharmacovigilance: What’s Coming Next
- From Academia to Entrepreneurship: Why I Left a 15-Year Professorship to Build InsilicomWhen I joined the Department of Statistics at Florida State University in 2007, I thought I’d spend my whole career in academia. Over 15 years, I moved from assistant to full professor, taught, advised students, and ran a lab. My journey didn’t start in statistics, though. I studied chemistry (BS, MS), computer science (MS), bioinformatics… Read more: From Academia to Entrepreneurship: Why I Left a 15-Year Professorship to Build Insilicom
- Did the U.S. just trade its strongest AI moat for short-term gains?When NVIDIA’s Jensen Huang said China is winning the AI race, he wasn’t entirely wrong. He just said it too early. The U.S. government’s decision to ban advanced NVIDIA chips from being sold to China was meant to slow China’s AI progress. It did, temporarily. But it also forced China to build its own chip… Read more: Did the U.S. just trade its strongest AI moat for short-term gains?
- SBIR/STTR Q&A: Common QuestionsAfter my last post on SBIR/STTR lessons, several people reached out with appreciation or follow-up questions. Here are the questions I received from Hua Jin and my answers. Q: How can I get involved as a reviewer? Contact program directors or officers directly. Let them know your expertise and interest. They are always looking for… Read more: SBIR/STTR Q&A: Common Questions
- How much knowledge are we missing when we rely only on public databases?Most biomedical knowledge graphs today are built from public databases, but few realize how incomplete these sources are compared to what’s published in PubMed literature. We recently compared our AI-extracted knowledge graph IKraph with 40+ public databases. The results were eye-opening 📊 Figure 1: Across five major relation types — gene–gene, chemical–chemical, gene–disease, chemical–disease, and… Read more: How much knowledge are we missing when we rely only on public databases?
- The Future of AI-Powered Pharmacovigilance: What’s Coming Next
